Characterization of Lipoprotein-associated phospholipase A2 in Serum in Patients with Stage 3-5 Chronic Kidney Disease

Abstract Background This study aims to test the Lp-PLA2 mass and activity in patients with CKD and to analyze their connection of Lp-PLA2with the development of disease and the occurrence of atherosclerosis in this population. Methods Fifty nine patients aged over 18 years and with a diagnosis of CKD were recruited. Kidney function was evaluated by serum creatinine, serum urea and estimated glomerular filtration rate (eGFR) according to CKD-EPI formula and clinical data was collected. Twenty four healthy volunteers served as healthy controls. Lp-PLA2 mass is measured by ELISA. Lp-PLA2 activity is determined by an enzymatic PAF-Acetylhydrolase assay. Results Serum mass and activity of Lp-PLA2 were higher in CKD patients compared to healthy controls ( p